23andMe ft. Anne Wojcicki - How a DNA startup took on the FDA and redefined health tech
Crucible Moments
Long Roads Lead to Meaningful Progress
23andMe is advancing its mission with the development of 23me 16, an investigational cancer drug that is currently entering phase two of testing. Phase one confirmed the safety and tolerability of the drug, while phase two will assess its effectiveness in treating advanced cancers. Although there's still a long journey ahead to validate its efficacy, the commitment to tackling complex challenges allows the company to recognize and appreciate the strides made in addressing significant health issues.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
